Effects on Serum Fractalkine by Diet and Omega-3 Fatty Acid Intervention: Relation to Clinical Outcome
Table 1
Baseline characteristics of the total study population ( = 563).
Age (y)
70.0 (67.5, 72.6)
Current smoker (%)
34
Body mass index (kg/m2)
26.5 (24.1, 28.7)
Metabolic syndrome (%)
39
Total cholesterol (mmol/L)
6.3 (5.7, 7.0)
LDL (mmol/L)
4.1 (3.5, 4.7)
HDL (mmol/L)
1.37 (1.15, 1.61)
Triglycerides (mmol/L)
1.53 (1.13, 2.04)
Fasting s-glucose (mmol/L)
5.6 (5.3, 6.2)
Systolic blood pressure (mmHg)
148 (135, 160)
Diastolic blood pressure (mmHg)
83.50 (91.00, 76.50)
Previous hypertension (%)
30
Previous diabetes (%)
15
Previous myocardial infarction (%)
18
Cardiovascular disease (%)
28
Aspirin (%)
26
Beta blocker (%)
17
ACE-I (%)
15
Calcium channel blocker (%)
16
Diuretic (%)
5
Nitrates (%)
9
Statins (%)
27
Data presented as percentages or median values (25, 75 percentiles). ACE-I: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; LDL: low density lipoprotein; HDL: high-density lipoprotein.
